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ABSTRACT
Objectives: The aims of the study is to analyze the effectiveness and safety of the use of intravaginal inserts with prosta-
glandin analogues: dinoprostone and misoprostol, in the labor induction.
Material and methods: Pregnant women (177), with use of dinoprostone (n = 69) or misoprostol (n = 108) for labor induc-
tion were analyzed.
Results: The length of time of delivery differed significantly between primiparous and multiparous women and depended 
on the type of prostaglandin. The incidence of cesarean sections did not differ significantly in analysed groups. The risk of 
failed induction was over two-fold higher in the dinoprostone group as compared to misoprostol. A statistically significant 
longer duration of the first and second stage of labor was observed in primiparous compared to multiparous women as 
well as differences of cervical ripening were observed. There was no statistically significant relationship between the oc-
currence of hyperstimulation and worsening the newborns condition determined after delivery.
Conclusions: Vaginal dinoprostone and misoprostol are equally safe in labor induction at term whereas dinoprostone is 
less efficacious for cervical ripening and shortening the time of labor. There was no advantage of any of the prostaglandins 
used in increasing the risk of having a child in a worse condition and increasing the percentage of caesarean sections.
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INTRODUCTION
Labor induction is one of the most common proce-
dures carried in obstetrics, and its main goal is to reduce 
the perinatal risk of a pregnant woman or her newborn 
through earlier pregnancy termination [1]. The development 
of perinatal surveillance techniques and popularization 
of ultrasound diagnostic methods in perinatology signifi-
cantly contributed to the more frequent decisions about 
these procedures. Labor induction is usually preceded by 
biochemical process leading to a multitude of changes of 
the cervix, referred as softening and repining [2, 3]. Of the 
many available possibilities, the intravaginal administration 
of prostaglandins (PG) is one of the most used methods [1]. 
About 10% of pregnant women undergo induction of labor 
preceded by ripening of the cervix and acceleration of its 
maturation with the use of PGE2 prostaglandins or their 
analogues [3]. The response of the cervix to prostaglandins 
differs in women and depends on its condition at the time of 
drug administration, week of gestation and individual char-
acteristics. The overall risk of ineffective preparation of the 
cervix within 12–24 hours of labor induction following the 
administration of vaginal prostaglandins (vPG) is 21.6% [4]. 
The cervical repining process begins several weeks before 
the onset of delivery, when an increase in the concentration 
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of proinflammatory myeloid and lymphoid phenotypes 
related cytokines, chemotaxis regulators and factors induc-
ing oxidative stress is observed [5, 6]. In turn, the lack of 
collagen cross-linked degradation together with the reduc-
tion of cell nuclei density in the stroma and the depletion 
of macrophage resources suggests blocking the cervical 
ripening process [2]. Macrophages, as myeloid-derived im-
mune cells, play an important regulatory role in the cervical 
tissue. Macrophages also have ability to produce nitric oxide 
(NO) and prostaglandins. Reduction in NO and PG synthesis 
inhibits the cervix maturation process. The inflammatory 
response process is particularly visible during the dilatation 
phase of the cervix, where an increase in inducible oxide 
synthetase (iNOS) is observed. Increased iNOS concentra-
tion enhances vasodilation, a mechanism facilitating tissue 
perfusion during labor and leukocyte inflow [7]. The pres-
ence of pro-inflammatory cells in the cervix in the antenatal 
period enables the action of paracrine factors (cytokines) 
influencing changes in the structure of the extracellular 
matrix. According to current research data, the cervical re-
modeling process is completed before delivery. Fibrous 
collagen from the stroma extracellular matrix is replaced 
by less cross-linked collagen [2]. The rearrangement and 
realignment of collagen fibrils as well as glycosaminogly-
can composition changes are first components of labor 
induction. High endogenous PG concentration in the cervix 
is due to increased cyclooxygenase-2 (COX-2) activity, de-
tected particularly before delivery. Contrary to COX-2, a de-
crease of 15-prostaglandin dehydrogenase (15-PGDH) has 
been observed, the role of which is to inactivate PG during 
and before the cervix maturation process [3, 8]. Excessively 
active 15-PGDH is therefore associated with the ineffective 
action of both endogenous and exogenous PG [3].
Exogenous PG, dinoprostone (PGE2 analog) and miso-
prostol (PGE1 analog), acting through receptors, stimulate 
signaling processes in various cells of the cervix [3].
MATERIAL AND METHODS
Out of the group of 800 women giving birth in the second 
half of 2019 in the Department of Perinatology, Obstet-
rics and Gynecology, 177 (22,1%) pregnant women were 
qualified for the observational study, who were between 
36 + 3 and 42 + 1 weeks of gestation (Tab. 1). Among the 
analyzed group of patients, 141 (79,7%) were primiparous, 
and 36 (20,3%) multiparous women. All examined women 
had an unfavorable cervix for labor, determined by Bishop’s 
score from 0 to 6 points (Mean 2,3) and required intravaginal 
administration of vPG in the form of an insert: Misoprostol 
(Misodel) at a dose of 200 µg (n = 108) or Dinoprostone 
(Cervidil) at a dose of 10 mg (n = 69) [reference group (vM) 
or study group(vD), respectively]. Exclusion study criteria 
were contraindications to the use of vPG: previous caesar-
ean section or scarred uteri, abnormal placenta implantation, 
non-cephalic presentation, fetal distress syndrome, cepha-
lopelvic disproportion. Women with premature rupture of 
membranes have been also excluded from the study analysis.
The indications for labour induction were based on 
A and B grade recommendations and consistent in all the 
pregnant women (Tab. 2).
Following administration of vPG, the continuous evalu-
ation of the fetus has been performed with cardiotocogra-
phy in all women. At the start of regular uterine contrac-
tions (more than three uterine contractions in the period 
of 10 minutes), the vPG has been retrieved and the patient 
was transferred to the delivery unit. In cases of fetal distress 
syndrome, fetal life-threatening signs, uterine tachysystole 
with fetal heart rate involvement or other indications for 
urgent termination of pregnancy, a caesarean section has 
been immediately performed. 
The study was approved by the ethical committee of 
Pomeranian Medical University and informed consent was 
obtained from all individual participants included in the 
study.
Statistical analysis
All continuous variables were checked for the normal-
ity of the distribution using the Kolmogorov-Smirnow test. 
The Student’s or Mann-Whitney’s t-tests were used to analyze 
statistical differences in the scores of two or more groups. 
To gain information about the relationship between the 
dependent and independent variables, the analysis of vari-
ance (ANOVA) or Kruskal-Wallis test was used. The χ2 Pearson 
test or Fisher’s exact test was used to study the statistical 
relationships between discontinuous variables and deter-
mine if there are nonrandom associations between two cat-
egorical variables. In order to estimate the risk of pathology 
depending on various factors, a logistic regression model 
was used. The results were described by giving the relative 
risk (OR) along with the 95% confidence intervals and the 
Table 1. Demographic characteristics of study population
Parameter vM (n = 108) vD (n = 69) p
Age [years] 23.8 ± 4.10 24.79 ± 4.94 N.S.
Maternal weight [kg] 68.2 ± 9.11 70.1 ± 5.18 N.S.
BMI 
[kg/m²]
< 30.0 (n = 166) 103 (95.4%) 63 (91.3%)
N.S.








Primipara (n = 36) 23 (21.3%) 13 (18.8%) N.S.
Multipara (n = 141) 85 (78.7%) 56 (81.2%) N.S.
Birthweight [g]
(range)




*p < 0.05; vM — reference group; vD — study group; N.S. — not significant
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*Intrapartum care: NICE guideline CG190 (February 2017); vM — reference 
group; vD — study group
probability. The probability in this model was calculated 
with the χ2 Pearson test or with Fisher’s two-sided test. 
The ROC (Receiver Operating Characteristic Curves) analysis 
was used to estimate the sensitivity and specificity for indi-
vidual ranges of the continuous variable values. The results 
were described by specifying the area under the curve, the 
probability p, and the coordinates of the ROC curves. Statisti-
cally significant differences in all tests were considered those 
for which the probability p <0.05. Statistical analyzes were 
performed using the statistical program STATA 11, license 
number 30110532736.
RESULTS
Our study analysis has demonstrated that the length 
of time from vPG administration to the onset of regular 
uterine contractions depended on the type of drug admin-
istered and differed significantly between primiparous and 
multiparous women. In primiparous women who received 
vM, the mean time to uterine contractions was statistically 
significantly shorter (p = 0.0173) compared to the vD group 
and amounted to 18.16 ± 24.04 h vs 22.73 ± 36.43 h, re-
spectively. On the other hand, in the group of multiparous 
women, the time to uterine contractions, both after vM and 
vD administration, did not differ significantly (Fig. 1).
In the group of all examined patients, 108 (61.02%) 
women gave birth by vaginal delivery, while 69 (38.98%) 
had a caesarean section. When analyzing the method of 
termination of pregnancy, the percentage of caesarean sec-
tions did not differ significantly (p = 0.506) in both groups 
of women receiving vD 29 (42.03%) and vM 40 (37.04%), 
which proves that both drugs show comparable influence 
on the effectiveness of vaginal delivery. The most frequent 
indications for caesarean section were: failure to progress in 
labor 25 (14.12%), fetal distress syndrome 19 (10.73%), cervi-
cal dystocia 15 (8.47%), fetal pelvic disproportion 4 (2.26%), 
fetal malposition 2 (1.13%), Indications for operative vaginal 
delivery (forceps or vacuum) were made in 7 (3.95%) women. 
The risk assessment of the presence of several factors in the 
group of women treated with vD compared to those treated 
with vM is presented in Table 3.
The risk of failed induction was over two-fold higher 
in the vD group as compared to vM and this relationship 
was statistically significant. In those cases, further medical 
procedures to increase the uterine contractibility have been 
required: oxytocin infusion or amniotomy. In the vD mul-
tipara group, the induction failure was more frequent than in 
the vM multipara group (25% vs 12,9%, respectively) (Tab. 4).
Compared to vM, the group of women receiving vD had 
also higher risk tendency of caesarean section or vaginal 
operative delivery, but this relationship was statistically 
insignificant. There was an over two-fold higher risk of failure 
to progress with vD compared to vM and this relationship 
was at the limit of statistical significance. In turn, the risk of 
a successful pre-induction was reduced (OR = 0.23) in the 
vD group compared to the vM group (Tab. 5). 
In the group of women treated with both vM and vD, 
a statistically significant longer duration of the first stage 
of labor (p = 0.0028) was observed in primiparous women 
(vM 5.93 h; vD 6.33 h) compared to multiparous women 
(vM 3.34 h; vD 3.49 h) (Fig. 2).
Similar relationships were observed in the second stage 
of labor. In the group of women treated with both vM and vD, 
a statistically significantly longer duration of the first stage 
of labor (p = 0.0001) was observed in primiparous women 
(vM 0.81 h; vD 1.06 h) compared to multiparous women 
(vM 0.26 h; vD 0.34 h) (Fig. 3).
In order to determine the cut-off value of continuous 
variables with respect to the drug (vD, vM), the ROC analy-
sis was used. In primiparous women with a duration of la-
bor ≥ 22.28 h, the sensitivity for vD was 69%. In turn, only 36% 
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Figure 1. Mean time since the vaginal prostaglandins administration to the beginning of labour in primipara and multipara groups; vD — study 
group; vM — reference group
Table 3. Determination of confidence interval for odds ratio as a measure of association between the presence of risk factors and their occurrence 
in the study group compared to reference group, calculated using the χ2 Pearson’s test or Fisher’s two-sided exact test
Dependent Variable Risk factors OR [95%] CI p
Occurrence in the vD group 
compared to vM grouzp
Induction of labour followed by amniotomy 2.18 1.11 4.27 0.023
Induction of labour followed by oxitocin infusion 2.61 1.36 5.01 0.004
Successful preinduction followed by vaginal birth 0.23 0.00 0.93 0.042
Caesarean section 1.23 0.66 2.28 N.S.
Vaginal operative delivery 1.18 0.26 5.45 N.S.
Cephalopelvic disproportion. 1.58 0.22 11.50 N.S.
Failure to progress in labour 2.24 0.95 5.28 0.064
Fetal distress 0.90 0.34 2.42 N.S.
Cervical dystocia 0.54 0.17 1.78 N.S.
vM — reference group; vD — study group; N.S. — not significant






Normal labor progress (n =  97) 74 (87.1) 23 (100)
N.S.
Failure to progress (n = 11) 11 (12.9) 0
vD
Normal labor progress (n = 55) 42 (75) 13 (100)
0.04
Failure to progress (n = 14) 14 (25) 0
vM — reference group; vD — study group; N.S. — not significant
of respondents who received vM had a delivery time ≥ 22.28 h 
(Specificity). For primiparous women, vD vs vM has a statisti-
cally significantly increased risk of prolonging the period of 
labor (first and second stage of labor time prolongation).
Statistically significant differences in cervical ripening were 
observed on the Bishop Score after administration of both vM 
and vD in primiparous and multiparous groups (Tab. 6), which 
proves that both drugs show high effectiveness in the area of 
the cervical tissue. In the group of primiparous women where 
a pregnancy was terminated by caesarean section, signifi-
cantly lower Bishop score values  were observed in comparison 
with vaginal deliveries, which indicates that the effectiveness 
of vaginal labor depends on the cervical ripening. This relation-
ship was not observed in multiparous women. 
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There were no significant differences between analyzed 
groups of women for postpartum hemorrhage and the 
rate was 18.5% (n = 20) and 20.3% (n = 14) for vM and vD 
respectively. There was also no statistically significant cor-
relation between the newborns’ birth condition in the Apgar 
score (3rd and 5th min.) on the degree of cervical ripening. 
The babies’ condition after birth has not been also related 
to the type of drug administered, duration of the I and II 
stage of labour, and the time from drug administration to 
delivery. Uterine hyperstimulation, understood as uterine 
contraction followed by pathological CTG recordings, oc-
curred in 14 (7.91%) women: 10 in vM and 4 in vD and 
the difference was not statistically significant (p = 0.69) in 
compared groups of patients. There was also no statistically 
significant relationship between the occurrence of hyper-
stimulation and parity, and its occurrence was not associated 
with worsening of newborns ‘condition determined at the 
3rd and 5th minutes of Apgar (p = 0.33) after delivery. 
DISCUSSION
The mean percentage of induced labour is in the range 
of about 20–25 percent, which signifies that every fifth 
pregnant woman is qualified to pregnancy termination 
before the onset of spontaneous uterine contractions [9]. 
In our material, this percentage was similar and did not differ 
from the data of other authors. Although the fetal-maternal 
indications for labour induction are well defined, there is still 
no clear consensus as to which of the available methods 
should be used. In our material, one of the most common 
indications for induction of labour was post-term pregnancy, 
which is consistent with the reports of other authors [10]. 
Mostly, pharmacological (prostaglandin analogs), mechani-
cal (eg Foley catheter) or simultaneously both methods are 
commonly used for labour induction [11].
In the case of labor induction, a particularly important 
element for the successful delivery is cervical ripening, 
a dynamic process accelerated by both endogenous and 
exogenous prostaglandins [3, 4, 11]. It seems that the rip-
ening of the cervix determines the quality and duration 
of labour as well as the need for additional stimulation of 
uterine contractions with oxytocin and the use of analge-
sics. Prostaglandins may be applied in the form of a gel to 
the cervical canal, vaginal insert or orally/ buccally titrated 
tablets. The most used are propstaglandin E1 E2 analogs: 
Table 5. Relationships between vPG and cervical repining according 
to the Bishop score (BS) in the studied groups of women
Para vPG BS n
The mean ± SD BS 
difference before 

















































vD — study group; vM — reference group
Figure 2. Mean time of the 1st stage of labour in primipara and multipara groups; vD — study group; vM — reference group
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Figure 3. Mean time of the 2nd stage of labour in primipara and multipara groups; vD — study group; vM — reference group
Table 6. Relationships between the mode of delivery and cervical 
repining according to the Bishop score (BS) in the studied groups 
of women
vPG Mode of delivery N
The mean ± SD BS difference 












2.43 ± 2.77 0.0420
vPG — vaginal prostaglandins; VB — vaginal birth; CC — caesarean section; 
vD — study group; vM — reference group
misoprostol and dinoprostone respectively [12]. Both 
drugs, apart from inducing uterine contractions, play 
a critical role in cervical ripening and softening [3, 9, 11]. 
Studies by Melamed et al. [13] proved that after prosta-
glandin E2 administration in a dose of 3 mg, an effective 
cervical ripening with favourable cervix to delivery was not 
achieved in 25% of pregnant women. The cervical ripening 
is a  complex biochemical reaction, the mechanism of ac-
tion of which is still not fully understood. An inflammatory 
process probably plays an important role, accompanied by 
an increase in the immune activity of cells and a change in 
their functions [14]. Yoshida et al. [15] found in an animal 
model that the softening phase of cervical remodeling 
is related to the decline of collagen cross-link density. 
At the same time, increased hydration of cervical cells was 
observed. This process may be modulated by changes in 
sex hormone levels leading to the activation of immune 
cells. In our study, a positive correlation was observed 
between the cervical ripening expressed with the Bishop 
scale and vaginally administrated prostaglandins. Our re-
sults, however, showed different dynamics of the action of 
two compared drugs. Misoprostol has shown greater ef-
fectiveness compared to dinoprostone, which is consistent 
with studies by other authors [16–18]. Its higher efficiency 
is manifested by a significant shortening of the delivery 
time, both in the first and the second stage of labor [18]. 
In consequence of a shortened stay in the maternity ward 
with accelerated delivery, the risk of vaginal operative 
delivery and cervical dystocia is reduced, as our research 
has also shown. It was calculated that vPG (especially vM 
versus vD) shortened the mean reduction in bed hours by 
nine and six hours in primiparous and multiparous women, 
respectively [18]. According to reports by other authors, 
shortened labour time reduces the risk of maternal infec-
tion and the need for antibiotics use [19]. In our studies, 
the mean time from vPG administration to the onset of 
labour differed significantly between primiparous and 
multiparous women. In the studies by Shmid et al. [17], 
similar statistically significant relationships were obtained: 
14.9 hours of primiparous women and 11.8 hours of mul-
tiparous women.
According to the research literature, the use of dinor-
postone compared to misoprostol is more often associated 
with the need to stimulate uterine contractions with oxyto-
cin [16, 20, 21], although some authors report no significant 
differences between these two prostaglandins use [22]. 
In our studies, oxytocin was used more than twice as often 
in the group of women induced with dinoprostone.
We found no correlation between the caesarean section 
rate and the type of vPG administered during labour induc-
tion. In a study by Schmidt et al. [17], caesarean section was 
performed in 31.1% of induced pregnancies (110/354), more 
often in primiparous women. In our study, the percentage of 
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caesarean sections was slightly higher (38.9%) and the most 
common indications for its performance were abnormal CTG 
recordings, no progression of labour or cervical dystocia.
There are reports that tachysystole and uterine hyper-
stimulation are more common in women induced with 
misoprostol compared to dinoprostone [22]. In a study by 
Wing et al. [21], tachysystole was present in 13.3% of women 
induced by misprostol (vaginal 200 mcg) vs 4.0% induced by 
dionoprostone (vaginal 10 mg). On the other hand, in the 
studies by Yehia et al. [20], no statistical differences were 
observed in the occurrence of uterine hyperstimulation in 
the groups of women undergoing induction with misopro-
stol and dinoprostone, which may be due to differences in 
the form and dose of drugs used: titrated oral misoprostol 
(20 mcg every 2 hours) and vaginal dinoprostone (3 mg). 
Other studies compared oral misoprostol (50mcg every 
4 hours), vaginal misoprostol (25–50mcg every 6 hours) with 
vaginal gel dinoprostone [23] or vaginal insert dinoprostone 
(10 mg) [9]. In all the studied groups, the authors did not 
find statistically significant differences in the occurrence 
of tachysystole and uterine hyperstimulation. Our stud-
ies have also shown no differences in the percentage of 
uterine hyperstimulation in the studied groups of women. 
A randomized clinical trial is currently in progress regard-
ing efficacy and safety of administering oral misoprostol 
by titration compared to vaginal misoprostol and dino-
prostone for cervical ripening and induction of labor [24]. 
Most studies reports do not show any increased risk of 
side effects of misoprostol compared to dinoprostone, as 
well as worse birth condition of the newborns, longer stay 
on NICU admission and higher neonatal mortality after 
induction of labor with misoprostol or dinoprostone [20, 
22, 23, 25]. In randomized studies of PLOS ONE — the me-
dian birth status of newborns on the Apgar scale at the first 
and fifth minutes of life did not differ significantly in the 
groups of mothers induced with prostaglandin analogues: 
oral or vaginal misoprostol and vaginal dinoprostone [23]. 
The use of exogenous prostaglandins does not affect the 
birth condition of newborns, regardless of the exposure 
time and the time of prostaglandin removal [25]. Similar 
results were obtained in our study, where the condition of 
newborns did not differ significantly in the studied groups.
Our research shows that both prostaglandins used, vM 
and vD are effective during labour induction and show 
a similar safety profile, which means that the use of phar-
macological methods for labour induction may be a safe 
treatment alternative to other methods.
CONCLUSIONS
Vaginal dinoprostone and misoprostol are equally safe 
in labour induction at term whereas dinoprostone is less 
efficacious for cervical ripening and shortening the time 
of labour. There was no advantage of any of the pros-
taglandins used in increasing the risk of having a child 
in a worse condition and increasing the percentage of 
caesarean sections.
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